GSK-3 inhibition in vitro and in vivo enhances antitumor effect of sorafenib in renal cell carcinoma (RCC)

Biochemical and Biophysical Research Communications

Volumn 423, Issue 3, 2012, Pages 490-495

  Kawazoe, Hisashi ^a   Bilim, Vladimir N ^a   Ugolkov, Andrey V ^b   Yuuki, Kaori ^a   Naito, Sei ^a   Nagaoka, Akira ^a   Kato, Tomoyuki ^a   Tomita, Yoshihiko ^a  

^a YAMAGATA UNIVERSITY   (Japan)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Glycogen synthase kinase 3; Renal cell carcinoma; Sorafenib; Tyrosine kinase inhibitor

Indexed keywords

1 (4 METHOXYBENZYL) 3 (5 NITRO 2 THIAZOLYL)UREA; 2 (2,4 DICHLOROPHENYL) 3 (1 METHYL 3 INDOLYL)MALEIMIDE; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3BETA; SORAFENIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; CARCINOMA, RENAL CELL; CELL PROLIFERATION; GLYCOGEN SYNTHASE KINASE 3; HUMANS; KIDNEY NEOPLASMS; MICE; PROTEIN KINASE INHIBITORS; PYRIDINES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84863314567     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.05.147     Document Type: Article

References (25)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics. CA Cancer J. Clin. 2012, 62:10-29.
2. Bukowski R.M. Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2. Cancer 1997, 80:1198-1220.
3. Bukowski R.M. Cytokine therapy for metastatic renal cell carcinoma. Semin. Urol. Oncol. 2001, 19:148-154.
4. Motzer R.J., Bukowski R.M. Targeted therapy for metastatic renal cell carcinoma. J. Clin. Oncol. 2006, 24:5601-5608.
5. Motzer R.J., Hutson T.E., Tomczak P., Michaelson M.D., Bukowski R.M., Oudard S., Negrier S., Szczylik C., Pili R., Bjarnason G.A., Garcia-del-Muro X., Sosman J.A., Solska E., Wilding G., Thompson J.A., Kim S.T., Chen I., Huang X., Figlin R.A. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 2009, 27:3584-3590.
6. Motzer R.J., Molina A.M. Targeting renal cell carcinoma. J. Clin. Oncol. 2009, 27:3274-3276.
7. Ljungberg B.J., Cowan N.C., Hanbury D.C., Hora M., Kuczyk M.A., Merseburger A.S., Patard J.-J., Mulders P.F.A., Sinescu I.C. EAU Guidelines on renal cell carcinoma: the 2010 update. Eur. Urol. 2010, 58:398-406.
8. Grünwald V., Kalanovic D., Merseburger A. Management of sunitinib-related adverse events: an evidence- and expert-based consensus approach. World J. Urol. 2010, 28:343-351.
9. Jope R.S., Johnson G.V. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem. Sci. 2004, 29:95-102.
10. Jope R.S., Yuskaitis C.J., Beurel E. Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. Neurochem. Res. 2007, 32:577-595.
11. Ougolkov A.V., Bone N.D., Fernandez-Zapico M.E., Kay N.E., Billadeau D.D. Inhibition of glycogen synthase kinase-3 activity leads to epigenetic silencing of nuclear factor {kappa}B target genes and induction of apoptosis in chronic lymphocytic leukemia B cells. Blood 2007, 110:735-742.
12. Ougolkov A.V., Fernandez-Zapico M.E., Bilim V.N., Smyrk T.C., Chari S.T., Billadeau D.D. Aberrant nuclear accumulation of glycogen synthase kinase-3beta in human pancreatic cancer: association with kinase activity and tumor dedifferentiation. Clin. Cancer Res. 2006, 12:5074-5081.
13. Ougolkov A.V., Fernandez-Zapico M.E., Savoy D.N., Urrutia R.A., Billadeau D.D. Glycogen synthase kinase-3beta participates in nuclear factor kappaB-mediated gene transcription and cell survival in pancreatic cancer cells. Cancer Res. 2005, 65:2076-2081.
14. Naito S., Bilim V., Yuuki K., Ugolkov A., Motoyama T., Nagaoka A., Kato T., Tomita Y. Glycogen synthase kinase-3beta: a prognostic marker and a potential therapeutic target in human bladder cancer. Clin. Cancer Res. 2010, 16:5124-5132.
15. Bilim V., Ougolkov A., Yuuki K., Naito S., Kawazoe H., Muto A., Oya M., Billadeau D., Motoyama T., Tomita Y. Glycogen synthase kinase-3: a new therapeutic target in renal cell carcinoma. Br. J. Cancer 2009, 101:2005-2014.
16. Panka D.J., Wang W., Atkins M.B., Mier J.W. The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells. Cancer Res. 2006, 66:1611-1619.
17. Panka D.J., Cho D.C., Atkins M.B., Mier J.W. GSK-3 inhibition enhances sorafenib-induced apoptosis in melanoma cell lines. J. Biol. Chem. 2008, 283:726-732.
18. Bhat R., Xue Y., Berg S., Hellberg S., Ormo M., Nilsson Y., Radesater A.-C., Jerning E., Markgren P.-O., Borgegard T., Nylof M., Gimenez-Cassina A., Hernandez F., Lucas J.J., Diaz-Nido J., Avila J. Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. J. Biol. Chem. 2003, 278:45937-45945.
19. Coghlan M.P., Culbert A.A., Cross D.A.E., Corcoran S.L., Yates J.W., Pearce N.J., Rausch O.L., Murphy G.J., Carter P.S., Roxbee Cox L., Mills D., Brown M.J., Haigh D., Ward R.W., Smith D.G., Murray K.J., Reith A.D., Holder J.C. Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem. Biol. 2000, 7:793-803.
20. Chang Y., Adnane J., Trail P., Levy J., Henderson A., Xue D., Bortolon E., Ichetovkin M., Chen C., McNabola A., Wilkie D., Carter C., Taylor I., Lynch M., Wilhelm S. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother. Pharmacol. 2007, 59:561-574.
21. Tamaskar I., Garcia J.A., Elson P., Wood L., Mekhail T., Dreicer R., Rini B.I., Bukowski R.M. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J. Urol. 2008, 179:81-86.
22. Lainakis G., Bamias A. Targeting angiogenesis in renal cell carcinoma. Curr. Cancer Drug Targets 2008, 8:349-358.
23. Ullen A., Farnebo M., Thyrell L., Mahmoudi S., Kharaziha P., Lennartsson L., Grander D., Panaretakis T., Nilsson S. Sorafenib induces apoptosis and autophagy in prostate cancer cells in vitro. Int. J. Oncol. 2010, 37:15-20.
24. Yang F., Brown C., Buettner R., Hedvat M., Starr R., Scuto A., Schroeder A., Jensen M., Jove R. Sorafenib induces growth arrest and apoptosis of human glioblastoma cells through the dephosphorylation of signal transducers and activators of transcription 3. Mol. Cancer Ther. 2010, 9:953-962.
25. Shiota M., Eto M., Yokomizo A., Tada Y., Takeuchi A., Masubuchi D., Inokuchi J., Tatsugami K., Kuroiwa K., Uchiumi T., Seki N., Naito S. Sorafenib with doxorubicin augments cytotoxicity to renal cell cancer through PERK inhibition. Int. J. Oncol. 2010, 36:1521-1531.